Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SGT-53 by SynerGene Therapeutics for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
SGT-53 is under clinical development by SynerGene Therapeutics and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According...